Upadacitinib (BioDeep_00000015149)
代谢物信息卡片
Upadacitinib
化学式: C17H19F3N6O (380.15723599999995)
中文名称: 乌帕替尼
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCC1CN(CC1C2=CN=C3N2C4=C(NC=C4)N=C3)C(=O)NCC(F)(F)F
InChI: InChI=1S/C17H19F3N6O/c1-2-10-7-25(16(27)24-9-17(18,19)20)8-11(10)13-5-22-14-6-23-15-12(26(13)14)3-4-21-15/h3-6,10-11,21H,2,7-9H2,1H3,(H,24,27)/t10-,11+/m1/s1
描述信息
L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors > D000075242 - Janus Kinase Inhibitors
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
D018501 - Antirheumatic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- KEGG: C72237
- KEGGdrug: D10994
- PubChem: 58557659
- DrugBank: DB15091
- ChEMBL: CHEMBL3622821
- CAS: 1310726-60-3
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Maddalena Napolitano, Silvia Mariel Ferrucci, Luciano Foggia, Katharina Hansel, Elena Pezzolo, Luca Stingeni, Elettra Antonelli, Vincenzo Picone, Cataldo Patruno. Comparison of Long-Term Effectiveness and Safety of Upadacitinib for Atopic Dermatitis Between Dupilumab-Exposed and Dupilumab-Naïve Patients.
Clinical drug investigation.
2024 Jan; 44(1):71-77. doi:
10.1007/s40261-023-01336-w. [PMID: 38105393] - Axel De Greef, Pierre-Dominique Ghislain, Laurence de Montjoye, Marie Baeck. Real-Life Effectiveness and Tolerance of Upadacitinib for Severe Atopic Dermatitis in Adolescents and Adults.
Advances in therapy.
2023 05; 40(5):2509-2514. doi:
10.1007/s12325-023-02490-5. [PMID: 36944819] - Jianfeng Yu, Yao Shen, Jiawei Luo, Juan Jin, Pengfei Li, Peida Feng, Huaijin Guan. Upadacitinib inhibits corneal inflammation and neovascularization by suppressing M1 macrophage infiltration in the corneal alkali burn model.
International immunopharmacology.
2023 Mar; 116(?):109680. doi:
10.1016/j.intimp.2023.109680. [PMID: 36739832] - Hanan S Anbar, Naglaa G Shehab, Nadia M M El-Rouby, Marium A Ansari, Haseena Chenoth, Maham Majeed, Komal Naeem, Fatima Hersi, Hany A Omar. Upadacitinib protects against cisplatin-induced renal and hepatic dysfunction without impairing its anticancer activity.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2022 May; 172(?):106149. doi:
10.1016/j.ejps.2022.106149. [PMID: 35189270] - Mohamed-Eslam F Mohamed, Insa Winzenborg, Ahmed A Othman, Patrick Marroum. Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development.
The AAPS journal.
2022 03; 24(2):39. doi:
10.1208/s12248-022-00681-6. [PMID: 35230556] - Jonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber, Weily Soong, Kenji Kabashima, Antonio Costanzo, David Rosmarin, Charles Lynde, John Liu, Amy Gamelli, Jiewei Zeng, Barry Ladizinski, Alvina D Chu, Kristian Reich. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results.
The Journal of allergy and clinical immunology.
2022 03; 149(3):977-987.e14. doi:
10.1016/j.jaci.2021.07.036. [PMID: 34403658] - Toshimasa Shimizu, Shin-Ya Kawashiri, Shuntaro Sato, Yurika Kawazoe, Shohei Kuroda, Rina Kawasaki, Yasuko Ito, Shimpei Morimoto, Hiroshi Yamamoto, Atsushi Kawakami. Discontinuation of methotrexate in rheumatoid arthritis patients achieving clinical remission by treatment with upadacitinib plus methotrexate (DOPPLER study): A study protocol for an interventional, multicenter, open-label and single-arm clinical trial with clinical, ultrasound and biomarker assessments.
Medicine.
2022 Jan; 101(2):e28463. doi:
10.1097/md.0000000000028463. [PMID: 35029189] - Jens Martens-Lobenhoffer, Stylianos Tomaras, Eugen Feist, Stefanie M Bode-Böger. Quantification of the janus kinase 1 inhibitor upadacitinib in human plasma by LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 Jan; 1188(?):123076. doi:
10.1016/j.jchromb.2021.123076. [PMID: 34871917] - Elena Muensterman, Benjamin Engelhardt, Sathej Gopalakrishnan, Jaclyn K Anderson, Mohamed-Eslam F Mohamed. Upadacitinib pharmacokinetics and exposure-response analyses of efficacy and safety in psoriatic arthritis patients - Analyses of phase III clinical trials.
Clinical and translational science.
2022 01; 15(1):267-278. doi:
10.1111/cts.13146. [PMID: 34464029] - Junwei Li, Chaojie Chen, Jing Wang, Zhize Ye, Lin Pan, Zhenbei Liu, Congrong Tang. Simultaneous measurement of upadacitinib and methotrexate by UPLC-MS/MS and its pharmacokinetic application in rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2022 Jan; 1188(?):123071. doi:
10.1016/j.jchromb.2021.123071. [PMID: 34875493] - Mohamed-Eslam F Mohamed, Sheryl Coppola, Tian Feng, Heidi S Camp, Elaine Kim, Ahmed A Othman. Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects.
Clinical pharmacology in drug development.
2021 11; 10(11):1335-1344. doi:
10.1002/cpdd.957. [PMID: 34109764] - Fredrik N Albach, Gerd R Burmester, Robert Biesen. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
Annals of the rheumatic diseases.
2021 10; 80(10):1361-1362. doi:
10.1136/annrheumdis-2021-220834. [PMID: 34167947] - Paqui G Traves, Bernard Murray, Federico Campigotto, René Galien, Amy Meng, Julie A Di Paolo. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Annals of the rheumatic diseases.
2021 07; 80(7):865-875. doi:
10.1136/annrheumdis-2020-219012. [PMID: 33741556] - Cláudia Monfroni Rocha, Alessandro Menna Alves, Beatriz Fabris Bettanin, Fernanda Majolo, Matthias Gehringer, Stefan Laufer, Márcia Inês Goettert. Current jakinibs for the treatment of rheumatoid arthritis: a systematic review.
Inflammopharmacology.
2021 Jun; 29(3):595-615. doi:
10.1007/s10787-021-00822-x. [PMID: 34046798] - Mohamed-Eslam F Mohamed, Sathej Gopalakrishnan, Henrique D Teixeira, Ahmed A Othman. Exposure-Response Analyses for Upadacitinib Efficacy in Subjects With Atopic Dermatitis-Analyses of Phase 2b Study to Support Selection of Phase 3 Doses.
Journal of clinical pharmacology.
2021 05; 61(5):628-635. doi:
10.1002/jcph.1782. [PMID: 33156550] - Mohamed-Eslam F Mohamed, Mukul Minocha, Sheryl Trueman, Tian Feng, Jeffrey Enejosa, Ogert Fisniku, Ahmed A Othman. Characterization of the Effect of Upadacitinib on the Pharmacokinetics of Bupropion, a Sensitive Cytochrome P450 2B6 Probe Substrate.
Clinical pharmacology in drug development.
2021 03; 10(3):299-306. doi:
10.1002/cpdd.844. [PMID: 32648334] - Meng-Jie Wang, Yu-Hang Zhao, Chen Fan, Ying-Jie Wang, Xin-Qi Wang, Xiang-Jun Qiu, Rui-Le Shen. Development of an UPLC-MS/MS Method for the Quantitative Analysis of Upadacitinib in Beagle Dog Plasma and Pharmacokinetics Study.
Drug design, development and therapy.
2021; 15(?):4167-4175. doi:
10.2147/dddt.s332282. [PMID: 34629864] - William J Sandborn, Subrata Ghosh, Julian Panes, Stefan Schreiber, Geert D'Haens, Satoshi Tanida, Jesse Siffledeen, Jeffrey Enejosa, Wen Zhou, Ahmed A Othman, Bidan Huang, Peter D R Higgins. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Gastroenterology.
2020 06; 158(8):2139-2149.e14. doi:
10.1053/j.gastro.2020.02.030. [PMID: 32092309] - Danielle Peterson, William Damsky, Brett King. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Journal of the American Academy of Dermatology.
2020 06; 82(6):e223-e226. doi:
10.1016/j.jaad.2020.03.099. [PMID: 32278797] - Ahmed Nader, Sven Stodtmann, Anna Friedel, Mohamed-Eslam F Mohamed, Ahmed A Othman. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Journal of clinical pharmacology.
2020 04; 60(4):528-539. doi:
10.1002/jcph.1550. [PMID: 31701537] - Ahmed Nader, Mohamed-Eslam F Mohamed, Insa Winzenborg, Eva Doelger, Peter Noertersheuser, Aileen L Pangan, Ahmed A Othman. Exposure-Response Analyses of Upadacitinib Efficacy and Safety in Phase II and III Studies to Support Benefit-Risk Assessment in Rheumatoid Arthritis.
Clinical pharmacology and therapeutics.
2020 04; 107(4):994-1003. doi:
10.1002/cpt.1671. [PMID: 31610021] - Mohamed-Eslam F Mohamed, Ben Klünder, Ana P Lacerda, Ahmed A Othman. Exposure-Response Analyses for Upadacitinib Efficacy and Safety in the Crohn's Disease CELEST Study and Bridging to the Extended-Release Formulation.
Clinical pharmacology and therapeutics.
2020 03; 107(3):639-649. doi:
10.1002/cpt.1668. [PMID: 31594037] - Mohamed-Eslam F Mohamed, Denise Beck, Heidi S Camp, Ahmed A Othman. Preferential Inhibition of JAK1 Relative to JAK3 by Upadacitinib: Exposure-Response Analyses of Ex Vivo Data From 2 Phase 1 Clinical Trials and Comparison to Tofacitinib.
Journal of clinical pharmacology.
2020 02; 60(2):188-197. doi:
10.1002/jcph.1513. [PMID: 31448433] - Mohamed-Eslam F Mohamed, Tian Feng, Jeffrey V Enejosa, Ogert Fisniku, Ahmed A Othman. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Journal of clinical pharmacology.
2020 01; 60(1):86-95. doi:
10.1002/jcph.1496. [PMID: 31378969] - Mohamed-Eslam F Mohamed, Ben Klünder, Heidi S Camp, Ahmed A Othman. Exposure-Response Analyses of Upadacitinib Efficacy in Phase II Trials in Rheumatoid Arthritis and Basis for Phase III Dose Selection.
Clinical pharmacology and therapeutics.
2019 12; 106(6):1319-1327. doi:
10.1002/cpt.1543. [PMID: 31194885] - Martin E Dowty, Tsung H Lin, Michael I Jesson, Martin Hegen, David A Martin, Vaibhav Katkade, Sujatha Menon, Jean-Baptiste Telliez. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
Pharmacology research & perspectives.
2019 12; 7(6):e00537. doi:
10.1002/prp2.537. [PMID: 31832202] - Katie Bechman, Sujith Subesinghe, Sam Norton, Fabiola Atzeni, Massimo Galli, Andrew P Cope, Kevin L Winthrop, James B Galloway. A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis.
Rheumatology (Oxford, England).
2019 10; 58(10):1755-1766. doi:
10.1093/rheumatology/kez087. [PMID: 30982883] - Sheryl Trueman, Mohamed-Eslam F Mohamed, Tian Feng, Ana Paula Lacerda, Thomas Marbury, Ahmed A Othman. Characterization of the Effect of Hepatic Impairment on Upadacitinib Pharmacokinetics.
Journal of clinical pharmacology.
2019 09; 59(9):1188-1194. doi:
10.1002/jcph.1414. [PMID: 30973649] - Ben Klünder, Rajendar K Mittapalli, Mohamed-Eslam F Mohamed, Anna Friedel, Peter Noertersheuser, Ahmed A Othman. Population Pharmacokinetics of Upadacitinib Using the Immediate-Release and Extended-Release Formulations in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I-III Clinical Trials.
Clinical pharmacokinetics.
2019 08; 58(8):1045-1058. doi:
10.1007/s40262-019-00739-3. [PMID: 30945116] - Mohamed-Eslam F Mohamed, Sheryl Trueman, Tian Feng, Jaclyn Anderson, Thomas C Marbury, Ahmed A Othman. Characterization of the Effect of Renal Impairment on Upadacitinib Pharmacokinetics.
Journal of clinical pharmacology.
2019 06; 59(6):856-862. doi:
10.1002/jcph.1375. [PMID: 30633369] - Mohamed-Eslam F Mohamed, Sheryl Trueman, Tian Feng, Alan Friedman, Ahmed A Othman. The JAK1 Inhibitor Upadacitinib Has No Effect on the Pharmacokinetics of Levonorgestrel and Ethinylestradiol: A Study in Healthy Female Subjects.
Journal of clinical pharmacology.
2019 04; 59(4):510-516. doi:
10.1002/jcph.1350. [PMID: 30500075] - Mohamed-Eslam F Mohamed, Jiewei Zeng, Patrick J Marroum, In-Ho Song, Ahmed A Othman. Pharmacokinetics of Upadacitinib With the Clinical Regimens of the Extended-Release Formulation Utilized in Rheumatoid Arthritis Phase 3 Trials.
Clinical pharmacology in drug development.
2019 02; 8(2):208-216. doi:
10.1002/cpdd.462. [PMID: 29688617] - Ben Klünder, Mohamed-Eslam F Mohamed, Ahmed A Othman. Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials.
Clinical pharmacokinetics.
2018 08; 57(8):977-988. doi:
10.1007/s40262-017-0605-6. [PMID: 29076110] - Mohamed-Eslam F Mohamed, Steven Jungerwirth, Armen Asatryan, Ping Jiang, Ahmed A Othman. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
British journal of clinical pharmacology.
2017 Oct; 83(10):2242-2248. doi:
10.1111/bcp.13329. [PMID: 28503781] - Mohamed-Eslam F Mohamed, Heidi S Camp, Ping Jiang, Robert J Padley, Armen Asatryan, Ahmed A Othman. Pharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.
Clinical pharmacokinetics.
2016 12; 55(12):1547-1558. doi:
10.1007/s40262-016-0419-y. [PMID: 27272171]